Prevalence of drugs used for chronic conditions after diagnosis of thyroid cancer: a register-based cohort study.

Autor:	Hegvik TA; Department of Global Public Health and Primary Care, University of Bergen, Bergen 5020, Norway.; Clinic of Surgery, St. Olav's University Hospital, Trondheim 7006, Norway., Zhou Y; Department of Global Public Health and Primary Care, University of Bergen, Bergen 5020, Norway.; Department of Statistics and Biostatistics, Cal State East Bay, Hayward, CA 94542, United States., Brauckhoff K; Department of Breast and Endocrine Surgery, Haukeland University Hospital, Bergen 5021, Norway.; Department of Clinical Sciences, University of Bergen, Bergen 5020, Norway., Furu K; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo 0473, Norway.; Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo 0473, Norway., Hjellvik V; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo 0473, Norway., Bjørge T; Department of Global Public Health and Primary Care, University of Bergen, Bergen 5020, Norway.; Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo 0379, Norway., Engeland A; Department of Global Public Health and Primary Care, University of Bergen, Bergen 5020, Norway.; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo 0473, Norway.
Jazyk:	angličtina
Zdroj:	European journal of endocrinology [Eur J Endocrinol] 2024 Aug 05; Vol. 191 (2), pp. 166-174.
DOI:	10.1093/ejendo/lvae092
Abstrakt:	Objective: Little is known about thyroid cancer survivors' risk of chronic conditions. We, therefore, investigated the prevalence of drugs used for chronic conditions among thyroid cancer patients using population-wide register data. Methods: We linked data from the Cancer Registry of Norway to the Norwegian Prescription Database and other databases for a study population of 3.52 million individuals, including 3486 individuals with thyroid cancer diagnosed during 2005-2019. Prevalence ratios (PRs) with 95% CIs of reimbursed prescribed drugs in thyroid cancer patients up to 15 years after thyroid cancer diagnosis were estimated by log-binomial regression, with the cancer-free population as reference. Results: Individuals (both males and females) with thyroid cancer had higher use of drugs for several chronic conditions in the years after diagnosis; eg, 5 years after thyroid cancer diagnosis, there was elevated use of drugs for hypoparathyroidism (PRmales = 35.4, 95% CI, 25.2-49.7; PRfemales = 42.8, 95% CI, 34.2-53.6), hypertension (PRfemales = 1.20, 95% CI, 1.12-1.28), anxiety and tension (PRmales = 4.01, 95% CI, 1.80-8.92; PRfemales = 2.01, 95% CI, 1.15-3.52), gastric acid disorders (PRmales = 1.52, 95% CI, 1.22-1.91; PRfemales = 1.45, 95% CI, 1.27-1.66), and pain (PRmales = 1.48, 95% CI, 1.11-1.97; PRfemales = 1.24, 95% CI, 1.08-1.42) as compared with the cancer-free population. In addition, males with thyroid cancer had long-term elevated use of drugs for depression (eg, year 10+, PRmales = 1.66, 95% CI, 1.06-2.59). Individuals with thyroid cancer also had higher use of drugs for several conditions prior to the thyroid cancer diagnosis, eg, hypertension, gastric acid disorders, and pain. Conclusions: Individuals diagnosed with thyroid cancer had elevated long-term use of drugs for several chronic conditions, as compared with the cancer-free population. Competing Interests: Conflict of interest: None declared. (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Endocrinology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu